Researchers developed SVCFit, a tool that tracks how prostate cancer evolves under treatment by analyzing large chromosomal rearrangements often missed by standard approaches. https://www.biorxiv.org/content/10.1101/2025.02.01.636056

Several exciting findings here, including that 3 mos of BAT can markedly change the clonal composition of metastatic prostate cancer in association with acquired therapy resistance. Very fun to work with @rachelkarchin.bsky.social and team! @pcf-science.bsky.social @hopkinsmedicine.bsky.social

We are excited to open a clinical trial to assess how metabolic changes induced by water-only fasting affects the immune response to prostate cancer. Spread the word – I’m happy to discuss with any interested candidates. clinicaltrials.gov/study/NCT068...

Thrilled to share a project that we envisioned over a decade ago to perform high purity/high specificity molecular analysis of circulating tumor cells! Led by the Dr. Marina Sharifi and Dr. Jamie Sperger and funded by Funded by PCF, NCI, DOD @theaacr.bsky.social urldefense.com/v3/__https:/...

The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement: https://buff.ly/4gRXNB8

But…..ok, ok, I’m convinced. Elegant and definitive. www.science.org/doi/10.1126/...

Fascinating and well written! Reminiscent of a patient from our rapid autopsy cohort with targetable truncal driver but remarkable “dead-end” CNA-quiet subclones in the primary that fail to metastasize despite aggressive histology. pubmed.ncbi.nlm.nih.gov/34568716/

Happy to share an educational case that demonstrates that selection can drive acquired therapy resistance in metastatic prostate cancer rdcu.be/d15Ph Wonderful collab with @rachelkarchin.bsky.social @davidesanin.bsky.social

Thanks for visiting and teaching us amazing science Nima!!